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Tumor necrosis factor inhibitors (TNFi) have become the cornerstone for the treatment of rheumatoid arthritis and other
systemic autoimmune conditions. However, these biologic DMARDs can lead to various opportunistic infections such as viral
infection, tuberculosis, and histoplasmosis. Furthermore, these biologics can also cause severe systemic inﬂammatory reactions
known as hemophagocytosis lymphohistiocytosis (HLH) that can lead to multiorgan failure and high mortality. Due to
overlapping clinical features and time-intensive microbiological culture methods, distinguishing between HLH and opportunistic
infections can be challenging early in the disease course. We present a similar situation with our patient where the patient met the
diagnostic criteria for HLH however was found to have disseminated histoplasmosis. This case uniquely evaluates the utility of the
HLH diagnostic criteria and hemophagocytosis for accurate diagnosis of HLH.

1. Introduction
Patients with rheumatoid arthritis who are on immunosuppressive medications such as tumor necrosis factor inhibitors (TNFi) are at increased risk for developing
infections. Fever and cytopenia should warrant a prompt
investigation as the diﬀerential diagnosis ranges from selflimiting viral infections to disseminated invasive infections
such as tuberculosis and histoplasmosis.

2. Case Presentation
A 63-year-old Caucasian female with established seropositive (+RF, +ACPA) rheumatoid arthritis for 11 years on
treatment with inﬂiximab and methotrexate (MTX; 20 mg/
week) presented with a 1.5-month history of fever, cough,
and dyspnea. She was initially suspected to have communityacquired pneumonia treated with antibiotics and systemic

steroids with transient improvement; however, her symptoms recurred. Initial lab tests showed anemia (Hb: 8.8) and
thrombocytopenia (platelet: 51) with an elevated ferritin of
28,000 ng/ml, low complements (C3: 21; C4: <2), low ﬁbrinogen, elevated CRP, normal lipids, and mildly elevated
liver enzymes. CT chest was remarkable for subpleural
opacity without parenchymal inﬁltrates. Her physical examination demonstrated chronic limited range of motion of
the left wrist and no active synovitis.
Due to signiﬁcant elevation in ferritin, recurrent fevers,
cytopenias, and failure to respond to antibiotics, secondary
hemophagocytic lymphohistiocytosis (HLH) was suspected,
with possible triggers being RA, immunosuppression, malignancy, and infection. Additionally, further testing demonstrated an elevated soluble IL-2 receptor (sIL-2) at
7970 U/ml (Ref: 45–1105 U/ml). Hence, the patient fulﬁlled 5
out of 8 HLH-2004 diagnostic criteria for HLH with elevated
ferritin, low ﬁbrinogen, fever, cytopenia (Hb < 9 and low

2
platelets), and elevated sIL-2 receptor. She was empirically
started on high-dose systemic glucocorticoids for management of HLH; however, she continued to experience recurrent high-grade fever. Due to suspicion for an underlying
infectious etiology of HLH, bone marrow biopsy was performed which revealed hypercellular bone marrow with
multiple fungal elements consistent with histoplasmosis
without evidence of hemophagocytosis. Subsequent urine
and blood cultures conﬁrmed disseminated histoplasmosis.
Antifungal treatment with intravenous amphotericin
was promptly initiated in the hospital; after adequate clinical
response, the patient was transitioned to itraconazole.
Inﬂiximab and MTX were held during antifungal treatment,
and the patient was switched to hydroxychloroquine. Her
infection was under control during her 9 months of followup with infectious disease, and she remained on antifungal
treatment indeﬁnitely.

3. Discussion
Biologic disease-modifying antirheumatic drugs (DMARDs)
have become the cornerstone for treatment of systemic
autoimmune disorders. With the advancement in technology and research, new biologics are emerging that help
improve the treatment and prognosis of autoimmune
conditions. However, these great beneﬁts are not without
signiﬁcant risks. One of the important side eﬀects associated
with the use of biologics is the risk for development of
opportunistic infections (OIs). Diﬀerent classes of biologics
diﬀer in their ability to cause OIs. Certain tumor necrosis
factor inhibitors (TNFi) such as inﬂiximab and adalimumab
are associated with higher risk of OI compared to etanercept
[1]. According to a recent meta-analysis of RA patients on
biologics, for every 1000 patients treated with biologics, 1.7
patients developed an OI (0.0017%) [2].
TNFi can lead to OIs due to direct inhibition of tumor
necrosis factor (TNF). TNF is essential for the formation of
granuloma and prevention of granulomatous infections such
as tuberculosis and histoplasmosis. Histoplasmosis is the
most common fungal OI with an estimated incidence of
18.78 per 100,000 persons (0.00018%), second only to tuberculosis with an incidence of 53.81 per 100,000 (0.00053%)
patients treated with inﬂiximab [3].
Histoplasmosis is a fungal infection that primarily involves the lungs. Symptoms associated with acute pulmonary histoplasmosis include fever, chills, cough, and
dyspnea that are similar to bacterial pneumonia. Mediastinal adenopathy, which is common in histoplasmosis, can
lead to pleuritic chest pain. Once the infection spreads
systemically, it targets several organs including the liver,
spleen, gastrointestinal tract, and bone marrow. Immunocompromised state, due to HIV or anti-TNF therapy,
increases the risk of systemic infection with histoplasmosis
[4]. Approximately 75% of histoplasmosis cases associated
with TNFi have disseminated disease with a mortality rate
of 3.2% [5]. Additional symptoms noted during the disseminated phase include fever, chills, fatigue, weight loss,
and anorexia. Physical examination typically reveals
lymphadenopathy and hepatosplenomegaly. Laboratory
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investigations are signiﬁcant for pancytopenia, transaminitis, hyperbilirubinemia, elevated lactate dehydrogenase, and hyperferritinemia [6]. The diagnosis is
conﬁrmed by urine and serum testing for histoplasma
antigen, as well as cultures from bronchoalveolar lavage
(BAL) for deﬁnitive microbial identiﬁcation and cytopathology [4]. However, these batteries of diagnostic tests are
time- and resource-consuming, and ﬁnal conﬁrmatory
results are often delayed. Due to clinical symptoms overlap
of disseminated histoplasmosis with hemophagocytic
lymphohistiocytosis (HLH), timely additional workup is
needed in suspected cases of HLH to distinguish between
the two, as the mortality associated with untreated HLH
can exceed 50% [7].
HLH should be considered in any patient with persistent fever, cytopenia, transaminitis, and hyperferritinemia [8]. These ﬁndings can overlap with those of
invasive histoplasmosis. RA patients on TNFi are at risk for
HLH [9]; however, there are no reported cases of HLH in
RA patients not on biologic DMARD. In contrast, both
pulmonary histoplasmosis and disseminated histoplasmosis have been reported in RA patients irrespective of
TNFi use [10]. Interestingly, there have been several reports
of histoplasmosis associated HLH infection dating back to
1993 [11].
HLH is characterized by widespread multiorgan inﬂammation that involves prolonged activation of antigen
presenting cells (i.e., macrophages and histiocytes) and
CD8+ T cells, in response to an antigen trigger. Natural killer
(NK) cells, which function to attenuate the inﬂammatory
signal, are found to be functionally deﬁcient in HLH [12].
The prolonged activation leads to excessive formation of
cytokines (“hypercytokinemia”) and multiorgan failure [12].
HLH is diagnosed using the HLH-2004 diagnostic criteria.
Traditionally, HLH was classiﬁed into primary form (usually
in kids; documented genetic changes and abnormal function
of NK and cytotoxic T cells) and secondary form, HLH mostly
seen in adults (HLH features in the presence of a trigger such
as infection, without the genetic changes). However, the genetic changes can be seen in adults as well, and thus, primary
and secondary forms of designations have now been corrected
to “genetic” and “acquired” forms of HLH [13].
HLH can be diagnosed either with
(1) genetic testing to check for molecular arrangement
consistent with primary HLH or
(2) 5 out of 8 of the following ﬁndings [14]:
(i) Fever
(ii) Splenomegaly
(iii) Cytopenia: aﬀecting 2 of 3 cell lines in the peripheral blood (hemoglobin in adults < 10 mg/dL,
platelets <100 ∗ 109/L, and neutrophils 1 ∗ 109/L)
(iv) Hypertriglyceridemia
(≥265 mg/dl)
and
hypoﬁbrinogenemia (<1.5 g/L)
(v) Hemophagocytosis in bone marrow, liver, or
spleen with no evidence of malignancy
(vi) Absence of or low natural killer (NK) cell
activity (local lab reference)
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(vii) Ferritin > 500 microgram/L
(viii) Soluble CD 25 (i.e., soluble IL-2 receptor) ≥
2400 U/ml
Hemophagocytosis on bone marrow biopsy is an important feature of HLH and considered the gold standard for
diagnosis. In hemophagocytosis, erythrocytes, leukocytes,
thrombocytes, and their precursors are engulfed by macrophages [15]. In addition to HLH, hemophagocytosis can
be seen on tissue biopsy in the setting of infection, bone
marrow hyperplasia, ineﬀective hematopoiesis, major surgery, blood transfusion, and chemotherapy. There is an
ongoing debate regarding the role of hemophagocytosis in
the diagnosis of HLH. A study evaluating 80 bone marrow
biopsies with hemophagocytosis concluded that pancytopenia and high-grade hemophagocytosis (deﬁned as severe
>5 histiocytes with hemophagocytosis/slide) may help distinguish between HLH and non-HLH etiologies [16]. In
contrast, another recent study analyzing 64 bone marrow
biopsies from 58 patients concluded that hemophagocytosis
does not reliably predict HLH [17].

4. Conclusion
This patient met the diagnostic criteria for HLH; however,
the bone marrow biopsy did not show hemophagocytosis.
Her treatment for HLH was initiated with immunosuppression without any response. Subsequently, she was
switched to antifungal therapy for disseminated histoplasmosis and showed excellent response. In the current diagnostic criteria of HLH, presence or absence of
hemophagocytosis does not mandate or refute the diagnosis
nor does it have any prognostic signiﬁcance. However, this
case was successfully treated with antifungal alone without
the need for additional immunosuppression. It is worth
exploring whether the absence of hemophagocytosis in HLH
has a clinical/prognostic signiﬁcance and would warrant a
diﬀerent treatment strategy, as in this case.
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